The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sangamo Therapeutics Inc

Nasdaq: SGMO
Last

(U.S.) $9.30

Today's change+0.10 +1.09%
Updated June 23 4:00 PM EDT. Delayed by at least 15 minutes.
 

Sangamo Therapeutics Inc

Nasdaq: SGMO
Last

(U.S.) $9.30

Today's change+0.10 +1.09%
Updated June 23 4:00 PM EDT. Delayed by at least 15 minutes.

Sangamo Therapeutics Inc Hits New 52-week High

Sangamo Therapeutics Inc closed up Friday by (U.S.)$0.10 or 1.09% to (U.S.)$9.30 and setting a new 52-week high. Over the last five days, shares have gained 24.83% and are currently 1.59% off of the 52-week high. Shares have outperformed the S&P 500 by 41.72% during the last year.

Key company metrics

  • Open(U.S.) $9.35
  • Previous close(U.S.) $9.20
  • High(U.S.) $9.45
  • Low(U.S.) $8.95
  • Bid / Ask(U.S.) $9.15 / (U.S.) $9.75
  • YTD % change+204.92%
  • Volume1,740,043
  • Average volume (10-day)1,929,745
  • Average volume (1-month)2,452,733
  • Average volume (3-month)1,231,493
  • 52-week range(U.S.) $2.65 to (U.S.) $9.45
  • Beta3.30
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.02
Updated June 23 4:00 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue3934
Total other revenue--------
Total revenue3934
Gross profit--------
Total cost of revenue--------
Total operating expense20192231
Selling / general / administrative75511
Research & development13141719
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-17-10-19-27
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-17-10-19-27
Income after tax-17-10-19-27
Income tax, total--000
Net income-17-10-19-27
Total adjustments to net income--------
Net income before extra. items-17-10-19-27
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-17-10-19-27
Inc. avail. to common incl. extra. items-17-10-19-27
Diluted net income-17-10-19-27
Dilution adjustment--------
Diluted weighted average shares71717170
Diluted EPS excluding extraordinary itemsvalue per share-0.23-0.14-0.27-0.38
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.23-0.14-0.27-0.38